Osteonecrosis is a condition in which degradation of bones occurs due to decrease of blood flow to bones in joints. Osteonecrosis is also known as avascular necrosis, aseptic necrosis, or ischemic necrosis. There are some risk factors associated with osteonecrosis such as alcohol use, injury to joints, increased pressure inside the bone, and steroidal medications. Some procedures such as chemotherapy, radiation therapy, and organ transplant are also found as the cause of osteonecrosis. The most common symptom associated with osteonecrosis is the occurrence of pain when putting weight on affected joints. Osteonecrosis can be diagnosed by bone biopsy, bone scan, computed tomography, magnetic resonance imaging and measuring the pressure inside the bone. University of California, Davis is in the process of developing LLP2A ALENDRONATE for the treatment of osteonecrosis. Bone Therapeutics SA is in the process of developing PREOB as a cell therapy for the treatment of osteonecrosis. Some of the companies/universities having the pipeline of osteonecrosis include Istituto Ortopedico Rizzoli, Bone Therapeutics S.A, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.